Gastroenterology · Ulcerative ColitisTrial Updateclinicalmid-term

Phase III Trial of Hemay005 in Chinese Patients with Ulcerative Colitis Initiated

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Ganzhou Hemay Pharmaceutical Co., Ltd1 signalView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/17/2026, 6:04:19 AM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of Phase III trial for Hemay005 in Chinese patients with ulcerative colitis is significant as it could reshape competitive dynamics in the gastroenterology market. Monitoring the trial's progress is essential for understanding potential impacts on market positioning and strategic partnerships. Regulatory context from FDA (FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes) supports the near-term read. Assessment grounded in 16 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial outcomes as they could influence market positioning and strategic partnerships in gastroenterology. The strongest clinical anchor is Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis (ClinicalTrials.gov), entity match (ganzhou hemay pharmaceutical co ltd). In Gastroenterology · Ulcerative Colitis, 3 regulatory and 2 competitive items passed relevance filtering for Ganzhou Hemay Pharmaceutical Co., Ltd.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway (Humanexa Signals) — entity match (ulcerative colitis). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This trial positions Hemay005 as a potential competitor in the ulcerative colitis market, particularly in the Chinese demographic.

Regulatory Outlook

Regulatory risk is concentrated around FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The trial's results will be critical for regulatory submissions and could influence the approval process for Hemay005 in the Chinese market.

Key Risks

Elevated medium regulatory exposure for Ganzhou Hemay Pharmaceutical Co., Ltd could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial outcomes could enhance market share for Hemay005, potentially affecting revenue streams for competitors in the ulcerative colitis treatment space.
How we engage and involve patients and the public in our regulatory decision-making.
Upside for Ganzhou Hemay Pharmaceutical Co., Ltd may improve if Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should monitor the trial outcomes as they could influence market positioning and strategic partnerships in gastroenterology.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and final efficacy data from the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.govhigh relevance
Entity match (ganzhou hemay pharmaceutical co ltd)
FDA document
View source
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.govhigh relevance
Entity match (ulcerative colitis)
FDA document
View source
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
ClinicalTrials.govhigh relevance
Entity match (ulcerative colitis)
FDA document
View source
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Left Atrial and Left Ventricular Structural and Functional Evaluation by CCTA for Predicting Post-Ablation Outcomes in Patients With Atrial Fibrillation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway
Humanexa Signalshigh relevance
Entity match (ulcerative colitis)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Influencing factors of oral frailty in Chinese maintenance hemodialysis patients: Bayesian network analysis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Ganzhou Hemay Pharmaceutical Co., Ltd
Ulcerative Colitis
Gastroenterology

Commercial impact

medium

Successful trial outcomes could enhance market share for Hemay005, potentially affecting revenue streams for competitors in the ulcerative colitis treatment space.

Regulatory impact

medium

The trial's results will be critical for regulatory submissions and could influence the approval process for Hemay005 in the Chinese market.

What to watch

Key milestones include interim results and final efficacy data from the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.